Small-cell Lung Cancer
Conditions
Keywords
SBRT, low dose radiotherapy, PARP inhibitor, PD-1,PD-L1
Brief summary
SCLC patients after initial treatment failure are treated with SBRT and low-dose radiotherapy concurrent with PARP inhibitors + temozolomide +PD-1/PD-L1 inhibitors for two cycles at least, then PARP inhibitors+temozolomide+PD-1/PD-L1 inhibitors two cycles, PD-1/PD-L1 inhibitors maintenance therapy lasted for up to 2 years.
Detailed description
SCLC is easy to relapse and drug resistance soon after initial treatment , although radiotherapy and chemotherapy is sensitive at first treatment. Topotecan monotherapy is recommended in the NCCN guidelines for second-line standard treatment and the CSCO SCLC guidelines for diagnosis and treatment 2020 edition, but its effective rate is low, 24% for platinum-sensitive relapse, 2-6% for platinum-resistant, overall PFS is about 3-4 months and OS is about 6-8 months. Although immunotherapy have been successful at the first-line and third-line treatments of SCLC in the extensive stage , the second-line treatment has not achieved a breakthrough, and the effective rate of third-line immune single drug is between 10-20%.It is an important challenge and breakthrough to effectively improve the efficacy and survival of second-line treatment of SCLC. Immunocombination therapy is an important strategy to improve the efficacy. Some studies have shown that PARP inhibitors and low-dose radiotherapy can improve the efficacy of immunotherapy. PARP inhibitors are not only sensitizers of chemoradiotherapy, but also immunomodulators. High dose radiotherapy has the effect of in situ vaccine and increases tumor antigen release presentation. Low dose radiotherapy promotes the penetration of immune cells into tumor stroma and tumor bed and increases immune response. The combination of high and low dose radiotherapy and immunization can improve the immune effect and increase the incidence of distant effect. So the objective of this study is to observe the efficacy and safety of second-line treatment of SCLC with SBRT and low-dose radiotherapy combined with PARP inhibitor + temozolomide and PD-1 /PD-L1 inhibitor.
Interventions
None listed
Sponsors
First Affiliated Hospital of Harbin Medical University
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Age ≥18 years old, ≤80 years old, expected survival ≥3 months;Pathologically confirmed SCLC with recurrence and metastasis after initial treatment;KPS score ≥70 points;Satisfied the following laboratory diagnostic indicators: hemoglobin ≥110g/L, leukocyte 4.0-10.0×109/L, neutrophils 2.0-7.5×109/L, platelet ≥100×109/L;Creatinine ≤ upper normal limit (UNL);ALT and AST≤2.5×UNL, alkaline phosphatase (ALP) ≤5×UNL, total bilirubin (TBIL) ≤ UNL;Signed informed consent. \-
Exclusion criteria
1. Pregnant or lactating women; 2. Secondary tumor; 3. HIV carriers; 4. Serious medical diseases such as heart and lung; 5. Patients with uncontrollable mental history, unable to cooperate with treatment; 6. Autoimmune system disease, symptomatic interstitial lung disease; 7. Patients with active infection, chronic infection, acute infection, etc., and body inflammation; 8. Patients who had used hormones or antibiotics 1 month prior to treatment. -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3 Month Objective Remission Rate | Up to 5 years | The patients have complete remission and partial remission on 3 months after radiotherapy and chemotherapy. |
| Progression-Free Survival | From chemotherapy completion until progress or death, assessed up to 5 years | Will be described using standard Kaplan-Meier methodologies. The median PFS time, 1-year rate, 3-year PFS rate and 5-year PFS rate will be estimated and presented with 90% confidence intervals. |
| Time To Progression | Up to 5 years | Time involved from research start until progress for tumor |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | From chemotherapy completion until death, assessed up to 5 years | Will be described using standard Kaplan-Meier methodologies. The median survival time, 1-year survival rate, 3-year survival rate , 5-year survival rate and will be estimated and presented with 90% confidence intervals. |
| Number of Participants With Serious Adverse Events Related to treatment | up to 5 years | Toxicity assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4 |
Contacts
Primary ContactLijun Tan, Dr.
Backup ContactChengling Chu, Dr.
Outcome results
None listed